224 related articles for article (PubMed ID: 31609741)
21. Angiogenesis and antiangiogenic agents in non-small cell lung cancer.
Galligioni E; Ferro A
Lung Cancer; 2001 Dec; 34 Suppl 4():S3-7. PubMed ID: 11742695
[TBL] [Abstract][Full Text] [Related]
22. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
23. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
24. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
25. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
Wozniak A
Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
[TBL] [Abstract][Full Text] [Related]
26. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
Scagliotti G; Govindan R
Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383
[TBL] [Abstract][Full Text] [Related]
27. Antivascular agents for non-small-cell lung cancer: current status and future directions.
Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
[TBL] [Abstract][Full Text] [Related]
28. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
Girard N
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
[TBL] [Abstract][Full Text] [Related]
30. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.
Horn L; Sandler A
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S68-73. PubMed ID: 17382027
[TBL] [Abstract][Full Text] [Related]
32. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
33. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Reinmuth N; Heigener D; Reck M
Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies in lung cancer.
Besse B; Ropert S; Soria JC
Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
[No Abstract] [Full Text] [Related]
36. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
37. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
38. Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
Herbst RS
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S50. PubMed ID: 21884998
[No Abstract] [Full Text] [Related]
39. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]